65,437 trials
Treatment Resistant Depression
Primary: Hamilton Rating Scale for Depression - 6 Items — 12.5555556; 12.7500000; 12.5909091; 12.6315789 units on a scale — p=0.14
Diabetes Mellitus, Type 1
Primary: Hemoglobin A1c (HbA1c) at 26 Weeks — 7.06; 7.43 percentage of HbA1c
Ulcerative Colitis
Primary: Relapse Free Survival Week 17-48 — 12; 12 Participants
Head and Neck Cancer
Primary: Progression-Free Survival (PFS) — 1.9; 2.0 months — p=0.0667
Relapsed Acute Leukemia · Refractory Acute Leukemia
Primary: Number of Participants With Dose Limiting Toxicity in Phase I — 0; 0; 0 Participants
Diabetes Mellitus, Type 1
Primary: Hemoglobin A1c (HbA1c) — 7.38; 7.61 percentage of HbA1c
Idiopathic Pulmonary Fibrosis
Primary: Relative Change From Baseline in High Resolution Computerized Tomography (HRCT) Quantitative Lung Fibrosis (QLF) Score at 6 Months — 11.407; 14.583 percent change
AOD Misuse · AOD Associated Consequences
Primary: Alcohol Use — 9.9; 13.4 drinks per week at follow-up month
Ocular Hypertension · Open-angle Glaucoma
Primary: Intraocular Pressure (IOP) — 23.42; 23.37; 22.28; 21.92 mmHg — p=<0.0001
Prostatic Neoplasms
Primary: Efficacy of Leuprolide Mesylate (LMIS 50mg) — 97.0 percentage of participants
Healthy Volunteer Study
Primary: Maximum Plasma Concentration (Cmax) — 37499.938; 26207.273; 34752.646; 26377.382 ng/mL
Rhinitis, Allergic, Perennial
Primary: Mean Change From Baseline (Day 1) Over the Entire Treatment Period in Daily, Reflective Total Nasal Symptom Scores (rTNSS) Over 6 Weeks — -2.69; -3.95 Scores on a scale…
Clostridium Difficile Infection
Primary: Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population — 81; 85.7 Percentage of participants
Advanced Breast Cancer
Primary: 16-week Progression-free Survival (PFS) Rate — 44.8 percentage of population
Chronic Stable Plaque Psoriasis
Primary: Efficacy (Percentage of Subjects With Treatment Success) — 30.1; 9.7 percentage of participants